The 36th Annual Meeting of the Japanese Society of Gastroenterological Carcinogenesis.

Toward the Realization of Precision Surgery: World-Class Translational Research with an All-Japan Effort

Venue: The Across Fukuoka, Fukuoka Japan
Date: December　16 and 17, 2025.

 

 

 

 

 

The Japanese Societyof Gastroenterological Carcinogenesis was established in 1989 as a research group to elucidate the "mechanisms of carcinogenesis and progression of gastrointestinal cancer." It became officially recognized as a society in 1997. Under the leadership of prominent figures, including the first President, Dr. Takeshi Ohara, and successive presidents who are renowned in the Japanese surgical field, the society has made significant contributions to its advancement. In January 2017, it became a general incorporated association and is widely recognized as a platform for in-depth discussions between basic researchers and clinicians, particularly surgeons.

 

In recent years, however, there has been a serious decline in research engagement among surgeons, compounded by an aging workforce and a noticeable decrease in the number of surgeons. To tackle these issues, the President of the Japanese Surgical Society, Dr. Akinobu Taketomi, has introduced initiatives such as incentive programs, work-life balance improvements, and early exposure education. Among these, the promotion of "Precision Surgery" stands out as a particularly noteworthy initiative aimed at making surgical procedures more precise and personalized.

 

The "Precision Medicine Initiative" announced by former U.S. President Barack Obama in 2015 sought to establish personalized medicine that takes into account patients' genetic information, lifestyle, and environmental factors. Specific examples include: Utilizing genomic analysis to identify the causes of diseases and therapeutic strategies, Advancing personalized medicine by considering drug efficacy and side effects,

Supporting research through large-scale data sharing, and Rapidly introducing cutting-edge medical technologies. These approaches have yielded significant results, particularly in cancer treatment and rare disease research.

 

As genomic information is utilized for drug selection tailored to individual patients, surgical procedures and treatments should also be personalized. Our society, under the commission of the Japan Surgical Society, has planned to introduce the latest global technologies and knowledge in translational research that may one day contribute to "Precision Surgery". We aim to foster discussions on how to utilize these findings effectively.

 

Through the efforts of an advisory committee established by our society, we have gathered intriguing, cutting-edge topics related to translational research that may contribute to Precision Surgery. The committee has also introduced excellent speakers and moderators. However, the actual realization of Precision Surgery will depend on the active contributions of all participants in this meeting.

 

We sincerely hope that this meeting will herald a new dawn for global surgery and open new chapters in cancer treatment science.

 

Koshi Mimori